2
Clinical Trials associated with Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital)A single-center, single-arm, open-label, dose escalation study for evaluating the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) in the treatment of patients with relapsed / refractory B cell malignancies
A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) for the treatment of patients with relapsed / refractory B cell malignancies
100 Clinical Results associated with Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital)
100 Translational Medicine associated with Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital)
100 Patents (Medical) associated with Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital)
100 Deals associated with Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital)